Navigation Links
AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Date:1/3/2008

TUCSON, Ariz., Jan. 3 /PRNewswire/ -- AmpliMed today reported one year survival results from a Phase I/II trial of its lead drug candidate, Amplimexon(R) (imexon for injection) in combination with dacarbazine in patients with unresectable stage III or stage IV metastatic malignant melanoma. Results from the full cohort of patients in both the Phase I and Phase II shows a 11.7 month overall mean survival for the entire patient set and a 22 month overall mean survival in the subset of patients with normal LDH levels. This compares favorably to historical controls of 8 months and 10 months, respectively, for patients treated with dacarbazine alone.

"The impact on overall survival demonstrated by Amplimexon in these trials is very promising and supports the need for a larger, randomized trial," said Ronald Garren, M.D., Chief Executive Officer of AmpliMed. "Amplimexon could represent a significant advance in the treatment of melanoma for which there have been no new treatments approved in the last decade."

Amplimexon is a small molecule drug that increases oxidative stress in tumor cells leading to mitochondrial damage and apoptosis. In preclinical in vitro and animal model studies it shows activity against human tumors including melanoma and is synergistic with alkylating agents including dacarbazine.

Fifty (50) patients were treated with Amplimexon at MTD (maximum tolerated dose) during the Phase II portion of the trial, receiving 250 mg/m2 of dacarbazine and 1,000 mg/m2 of Amplimexon for 5 consecutive days every 3 weeks. Phase II was designed to preliminarily evaluate the efficacy of the Amplimexon/dacarbazine combination in metastatic malignant melanoma, in addition to safety. The criteria utilized for efficacy evaluation was RECIST. A total of 68 patients were enrolled at 13 U.S. centers in the Phase I and Phase II portions of the study.

Clinical Trial Results. The drug combination of Amplimexon and dacarbazine was well tolerated, with only 10.8 percent of patients showing myelosuppression and only 7 patients having serious adverse events likely related to the study drug. An objective response plus stable disease rate of 30.9 percent was observed for all treated patients (N = 68). The median overall survival of all patients was 11.7 months compared to approximately 8 months for dacarbazine treated historical controls. There was a minimum patient follow up of 1 year.

Subsets of patients having a normal serum LDH or alternatively an elevated LDH were also analyzed for median overall survival. The median overall survival of the 31 patients in the Amplimexon/dacarbazine group with a normal LDH was 22.5 months compared to 10 months for a dacarbazine monotherapy historical control group having a normal LDH. The median survival was 4.8 months for patients having an elevated LDH, no different than the historical control group receiving dacarbazine monotherapy.

"In addition to the positive survival advantage observed for patients with less advanced disease, I am particularly impressed with the relatively infrequent side-effects of Amplimexon across the entire set of patients treated, even when administered with full dose standard chemotherapy," said Evan M. Hersh, M.D., Chief Medical Officer of AmpliMed Corporation. "We look forward to evaluating Amplimexon in a larger, confirmatory trial and are excited by the potential this product candidate may offer to patients with malignant melanoma the most serious form of skin cancer."

About Metastatic Melanoma

Metastatic melanoma is the most deadly form of skin cancer, afflicting approximately 8,000 patients per year in the U.S. Based on statistics from the American Cancer Society, melanoma represents about 5% of all skin cancers, but causes almost 75% of all skin cancer related deaths. Whereas localized melanomas are largely curable by surgery, metastatic melanoma has a poor prognosis and there are few effective treatments. This results in an average survival time of 6.2 to 7.8 months in large multicenter studies. Two drugs are FDA-approved to treat metastatic melanoma: the alkylating agent dacarbazine, and the immunotherapy agent interleukin-2. Dacarbazine as a single agent has minimal activity and interleukin 2 is not widely used because of substantial toxicity. There have been no new treatments for metastatic melanoma approved by the FDA in over 10 years. In studies of dacarbazine as a single agent to treat malignant melanoma, median overall survival has ranged from 6-8 months.

About Amplimexon

Amplimexon is AmpliMed's parenteral formulation of imexon. Imexon is a cyanoaziridine compound which showed tantalizing evidence of activity in limited studies in lung cancer, melanoma and breast cancer that were documented in publications in the 1980s. The potential of imexon as a cancer drug was never fully explored, until 1994, when AmpliMed co-founding scientists Drs. Evan Hersh, David Alberts, Robert Dorr and William Remers initiated a program to decipher Amplimexon's novel mechanism of action. This led to the initiation in 2003 of a Phase I clinical study of the drug as a stand-alone therapy in late-stage cancer patients. Further preclinical research revealed that the combined use of Amplimexon and certain other chemotherapeutics resulted in a significant increase in efficacy compared to either drug alone. These findings are now being translated into a series of Phase I/II clinical studies of combination therapy in patients with various types of cancer.

About AmpliMed Corporation

AmpliMed Corporation was founded in 1989 with the support of the University of Arizona Technology Development Corporation and is focused on the clinical development of chemotherapeutic agents for cancer. AmpliMed's strategy is to develop anti-cancer drugs with novel mechanisms of action designed to overcome some of the limitations, such as myelosuppression (suppression of blood cell counts), multi-drug resistance (treatment-induced resistance to many cancer drugs) and cardiac toxicity, frequently associated with current cancer therapy. The company's lead product, Amplimexon (imexon for inj.), is in Phase II clinical trials. AmpliMed Corporation is based in Tucson, Arizona and is on the Web at http://www.amplimed.com.

Note that the data represented is this press release is provided as a snapshot of unaudited data, and thus final results may be marginally different after all auditing activities are concluded.

AmpliMed, Amplimexon and Amplizone are United States trademarks of AmpliMed Corporation.

Media Contact:

Julie Rathbun

Rathbun Communications

(206) 769-9219

julie@rathbuncomm.com


'/>"/>
SOURCE AmpliMed Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Immunosyn Corporation Releases SF-1019 Study Results
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
3. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
4. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
5. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
7. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. CEL-SCI Corporation Releases Letter to Shareholders
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):